202 related articles for article (PubMed ID: 37988189)
1. Inhibiting KLRB1 expression is associated with impairing cancer immunity and leading to cancer progression and poor prognosis in breast invasive carcinoma patients.
He JR; Li D; Zhang QX; Liu T; Ding Y; Wu CY; Chen SS; Chen JL
Aging (Albany NY); 2023 Nov; 15(22):13265-13286. PubMed ID: 37988189
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of KLRB1 is associated with increased cell growth, metastasis, poor prognosis, as well as a dysfunctional immune microenvironment in LUAD.
Chen JL; Wu CY; Luo XY; Wang XY; Wang FM; Huang X; Yuan W; Guo Q
Sci Rep; 2024 May; 14(1):11782. PubMed ID: 38782996
[TBL] [Abstract][Full Text] [Related]
3. Machine learning immune-related gene based on KLRB1 model for predicting the prognosis and immune cell infiltration of breast cancer.
Huang G; Xiao S; Jiang Z; Zhou X; Chen L; Long L; Zhang S; Xu K; Chen J; Jiang B
Front Endocrinol (Lausanne); 2023; 14():1185799. PubMed ID: 37351109
[TBL] [Abstract][Full Text] [Related]
4. NEFM DNA methylation correlates with immune infiltration and survival in breast cancer.
Li D; Zhao W; Zhang X; Lv H; Li C; Sun L
Clin Epigenetics; 2021 May; 13(1):112. PubMed ID: 34001208
[TBL] [Abstract][Full Text] [Related]
5. Low expression of
Liu X; Cui Q; Qin N
Transl Cancer Res; 2024 Mar; 13(3):1225-1240. PubMed ID: 38617516
[TBL] [Abstract][Full Text] [Related]
6. Establishing the role of BRCA1 in the diagnosis, prognosis and immune infiltrates of breast invasive cancer by bioinformatics analysis and experimental validation.
Li L; Li S; Zhang X; Mei L; Fu X; Dai M; Wei N
Aging (Albany NY); 2024 Jan; 16(2):1077-1095. PubMed ID: 38224491
[TBL] [Abstract][Full Text] [Related]
7. ACE2 maybe serve as a prognostic biomarker in breast invasive carcinoma.
Ling J; Peng N; Luo L
J Clin Lab Anal; 2022 Jun; 36(6):e24362. PubMed ID: 35373393
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of KLRB1 and its further association with immune cells in breast cancer.
Xu N; Meng X; Chu H; Yang Z; Jiao Y; Li Y
PeerJ; 2023; 11():e15654. PubMed ID: 37520246
[TBL] [Abstract][Full Text] [Related]
9. Integrated pancancer analysis reveals the oncogene characteristics and prognostic value of DIP2B in breast cancer.
Song C; Shang F; Tu W; Liu X
BMC Cancer; 2023 Mar; 23(1):296. PubMed ID: 37004015
[TBL] [Abstract][Full Text] [Related]
10. High expression of eIF4E is associated with tumor macrophage infiltration and leads to poor prognosis in breast cancer.
Li F; Sun H; Li Y; Bai X; Dong X; Zhao N; Meng J; Sun B; Zhang D
BMC Cancer; 2021 Dec; 21(1):1305. PubMed ID: 34876062
[TBL] [Abstract][Full Text] [Related]
11. Systematic Pan-Cancer Analysis of KLRB1 with Prognostic Value and Immunological Activity across Human Tumors.
Cheng X; Cao Y; Wang X; Cheng L; Liu Y; Lei J; Peng W; Shi D
J Immunol Res; 2022; 2022():5254911. PubMed ID: 35028320
[TBL] [Abstract][Full Text] [Related]
12.
Liang C; Chen Y; Chen S; She J; Shi Q; Wang P
Transl Cancer Res; 2023 Dec; 12(12):3641-3652. PubMed ID: 38192989
[TBL] [Abstract][Full Text] [Related]
13. Polo-like kinase 1 as a biomarker predicts the prognosis and immunotherapy of breast invasive carcinoma patients.
Shen J; Zhang W; Jin Q; Gong F; Zhang H; Xu H; Li J; Yao H; Jiang X; Yang Y; Hong L; Mei J; Song Y; Zhou S
Oncol Res; 2023; 32(2):339-351. PubMed ID: 38186570
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
15. Identification of Five Immune-Related lncRNAs Predicting Survival and Tumor Microenvironment Characteristics in Breast Cancer.
Xiao R; Yang M; Tan Y; Ding R; Li D
Comput Math Methods Med; 2021; 2021():6676692. PubMed ID: 33727952
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis reveals a prognostic and therapeutic biomarker CD3D in the breast carcinoma microenvironment.
Zhu Z; Ye W; Wu X; Lin S; Xu J; Li L; Li J; Wang H; Huang Z
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33350431
[TBL] [Abstract][Full Text] [Related]
17. Calreticulin, a potential coregulator of immune checkpoints and biomarker associated with tumor microenvironment and clinical prognostic significance in breast invasive carcinoma.
Lin J; Chen Y; Zhang Z; Qi F; Zhang M
Environ Toxicol; 2024 May; 39(5):2717-2731. PubMed ID: 38247288
[TBL] [Abstract][Full Text] [Related]
18. Ceruloplasmin correlates with immune infiltration and serves as a prognostic biomarker in breast cancer.
Chen F; Han B; Meng Y; Han Y; Liu B; Zhang B; Chang Y; Cao P; Fan Y; Tan K
Aging (Albany NY); 2021 Aug; 13(16):20438-20467. PubMed ID: 34413268
[TBL] [Abstract][Full Text] [Related]
19. Gene expression patterns associated with tumor-infiltrating CD4+ and CD8+ T cells in invasive breast carcinomas.
Wang Z; Yang X; Shen J; Xu J; Pan M; Liu J; Han S
Hum Immunol; 2021 Apr; 82(4):279-287. PubMed ID: 33612391
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of S1PR1 and its correlation with immune infiltrates in breast and lung cancers.
Zhong L; Xie L; Yang Z; Li L; Song S; Cao D; Liu Y
BMC Cancer; 2020 Aug; 20(1):766. PubMed ID: 32799825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
